. >> there's a county argument that the eli lilly and some of the astra seneca has put all this moneyinto research and finding a cure to problematics. they should have the right to market and sell the product. >> that's an argument that has so shortage of representatives and when you look at the way it's been written, this was the monopoly. we grant patents to renovators during that time. to be sold in any after that. after the monopoly. one of the things that impelled me in writing this book is realizing that we have come to accept a natural two-part lifecycle on how drugs work. an innovative company like eli lilly, the pfizer of the world works a but we need to recruit those costs once it's drugs on the available market. survey of the the first patent protected lifecycle and is available at a high price. it rewards innovation at the cost of access. at the end of the patent monopoly, we have a pathway for generic competition to assume more and more competitors will come in the price will come down and reach an affordable level and that emphasizes access. in easizes access. in effect,